These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29676941)

  • 1. PK/PD evaluation of fimasartan for the treatment of hypertension Current evidences and future perspectives.
    Angeli F; Verdecchia P; Trapasso M; Pane M; Signorotti S; Reboldi G
    Expert Opin Drug Metab Toxicol; 2018 May; 14(5):533-541. PubMed ID: 29676941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fimasartan: A New Angiotensin Receptor Blocker.
    Lee HY; Oh BH
    Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration.
    Paik SH; Chi YH; Lee JH; Han HS; Lee KT
    Biol Pharm Bull; 2017; 40(7):992-1001. PubMed ID: 28674263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
    Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
    Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.
    Rhee MY; Baek SH; Kim W; Park CG; Park SW; Oh BH; Kim SH; Kim JJ; Shin JH; Yoo BS; Rim SJ; Ha JW; Doh JH; Ahn Y; Chae JK; Park JB; Kim SK; Kim CH
    Drug Des Devel Ther; 2015; 9():2847-54. PubMed ID: 26082615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
    Jeon H; Lim KS; Shin KH; Kim J; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2012 Jan; 59(1):84-91. PubMed ID: 21934629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and metabolite profiling of fimasartan, a novel antihypertensive agent, in rats.
    Kim TH; Shin S; Bashir M; Chi YH; Paik SH; Lee JH; Choi HJ; Choi JH; Yoo SD; Bulitta JB; Ma E; Joo SH; Shin BS
    Xenobiotica; 2014 Oct; 44(10):913-25. PubMed ID: 24786684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers.
    Yi S; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):682-9. PubMed ID: 21394036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of age on the pharmacokinetics of fimasartan (BR-A-657).
    Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Cho JY; Yu KS; Yoon YR
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1337-44. PubMed ID: 21950382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fimasartan, a novel angiotensin II receptor antagonist.
    Kim JH; Lee JH; Paik SH; Kim JH; Chi YH
    Arch Pharm Res; 2012 Jul; 35(7):1123-6. PubMed ID: 22864732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fimasartan.
    Am J Cardiovasc Drugs; 2011 Aug; 11(4):249-52. PubMed ID: 21740078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
    Ruilope L
    J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.
    Oh GC; Joo KW; Kim MA; Choi DJ; Kim YJ; Lee HY
    Drug Des Devel Ther; 2020; 14():1341-1349. PubMed ID: 32308367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects.
    Ghim JL; Paik SH; Hasanuzzaman M; Chi YH; Choi HK; Kim DH; Shin JG
    J Clin Pharmacol; 2016 May; 56(5):576-80. PubMed ID: 26272450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fimasartan for independent reduction of blood pressure variability in mild-to-moderate hypertension.
    Shin MS; Kang DR; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Joo SJ; Lee SH; Hwang KK; Park JB
    Drug Des Devel Ther; 2016; 10():1573-80. PubMed ID: 27217724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
    Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
    Park JB; Sung KC; Kang SM; Cho EJ
    Am J Cardiovasc Drugs; 2013 Feb; 13(1):47-56. PubMed ID: 23344912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.